Targeting Mutant p53 by a SIRT1 Activator YK-3-237 Inhibits the Proliferation of Triple-Negative Breast Cancer Cells

Many types of mutations in tumor suppressor p53 are oncogenic through gain-of-function. Therefore, targeting mutant p53 (mtp53) is a promising therapeutic approach to fight against many types of cancers. We report here a small molecule compound YK-3-237 that reduces acetylation of mtp53 and exhibits...

Descripción completa

Detalles Bibliográficos
Autores principales: Yi, Yong Weon, Kang, Hyo Jin, Kim, Hee Jeong, Kong, Yali, Brown, Milton L., Bae, Insoo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2013
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759676/
https://www.ncbi.nlm.nih.gov/pubmed/23846322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3759676/
https://www.ncbi.nlm.nih.gov/pubmed/23846322

Ejemplares similares